Nykode Enters New Phase With Regeneron Vaccine Pact
US Major Pays $30m Upfront And Takes Stake
Regeneron is investing heavily to advance five vaccine programs with Nykode Therapeutics, the Norwegian company formerly known as Vaccibody.
You may also be interested in...
Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.
The German major is investing heavily in cancer R&D and has opened the doors of a new facility in the biotech epicenter on the east coast of the US.
The selection of nadulonimab by the Pancreatic Cancer Action Network for its adaptive clinical trial is a strong validation of the Stockholm-based firm's compound, which is also being evaluated for lung cancer.